


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (previously presented) A compound of formula (I), or an enantiomer or diastereoisomer thereof:



(I)

wherein:

A is a 5- or 6-membered carbocyclic ring;

X is H and W is OH; or X and W together form a carbonyl group or an epoxide;

R¹ is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl (e.g. trifluoromethyl); or –C(O)R² wherein R² is lower alkyl, aryloxy or benzyloxy;

Y is phenyl optionally mono- or di-substituted with R⁵ or C(O)R⁶, wherein R⁵ is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R⁶ is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered carbocyclic ring;

R³ is selected from the group consisting of: aryl, mono- or di-substituted with:









Het, said Het optionally mono- or di-substituted with lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile, trifluoromethyl, C(O)R⁶ wherein R⁶ is as defined above;

wherein each Het is independently a five-membered, unsaturated heterocycle containing from one to three heteroatoms selected from nitrogen, oxygen and sulfur;

and

R⁴ is a carboxylic acid, a salt or an ester thereof.

2. (original) A compound selected from:



wherein A, X, R¹, Y, R³, and R⁴ are as defined in claim 1.

3. (original) A mixture of compound I(a) and compound I(b), each according to claim 2.


4. (original) A mixture of compound I(c) and compound I(d), each according to claim 2.

5. (original) A compound mixture according to claim 3, wherein said mixture is racemic.

AMENDMENT

U.S. Appln. No. 10/772,721

6. (original) A compound mixture according to claim 4, wherein said mixture is racemic.
7. (original) A compound I(a) according to claim 2, as a pure enantiomer.
8. (original) A compound I(b) according to claim 2, as a pure enantiomer.
9. (original) A compound I(c) according to claim 2, as a pure enantiomer.
10. (original) A compound I(d) according to claim 2, as a pure enantiomer.
11. (original) A compound according to claim 1 wherein X is H and W is OH; or X and W form a carbonyl group.
12. (original) A compound according to claim 9 wherein X and W form a carbonyl group.
13. (original) A compound according to claim 1 wherein ring A is a benzene ring, as represented by the formula I':



wherein X, R¹, W, Y, R³, and R⁴ are as defined in claim 1.

14. (original) A compound according to claim 1, wherein R¹ is H; or one or two substituents independently selected from the group consisting of: hydroxy; halo; lower alkyl; lower alkoxy; lower thioalkyl; haloalkyl; or -C(O)R² wherein R² is lower alkyl, aryloxy or benzyloxy.
15. (original) A compound according to claim 14, wherein R¹ is H, halo or C₁₋₄ alkyl.

16. (original) A compound according to claim 15, wherein R¹ is H, fluoro or methyl.

17. (original) A compound according to claim 16, wherein R¹ is H or methyl.


18. (previously presented) A compound according to claim 1, wherein Y is phenyl optionally mono- or di-substituted with R⁵ or C(O)R⁶, wherein R⁵ is lower alkyl, lower cycloalkyl, lower alkoxy, halo, hydroxy, nitrile or trifluoromethyl, and R⁶ is lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy or trifluoromethyl; said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered carbocyclic ring.

19. (currently amended) A compound according to claim 18, wherein Y is naphthyl, or phenyl, wherein the phenyl ring is optionally mono- or di-substituted at the 3, 4, or 5 position with R⁵, wherein R⁵ is halo, C₁₋₄ alkyl, hydroxy, or CF₃ ~~or NHC(O)-(lower alkyl)~~.


20. (currently amended) A compound according to claim 19, wherein Y is phenyl optionally substituted with: 3,4-Cl; 3-F,4-Cl; 3-Cl,4-F; 3,4-Br; 3-F,4-CH₃; 3,4-CH₃; or 3-CF₃ ~~or NHC(O)-(CH₂)₃CH₃~~.

21. (original) A compound according to claim 20, wherein Y is phenyl optionally substituted with: 3,4-Cl or 3,4-Br.




22. (original) A compound according to claim 1, wherein R³ is:




23. (previously presented) A compound selected from the group consisting of: compounds having the following formula:



, wherein R^{4A} , R^1 , R^5 and R^3 are as defined as follows:

Cpd #	R^{4A}	R^1	-- R^5	-- R^3
1052	Na	--	3,4-Cl	
1076	Na	--	3,4-Br	
1083	Na	--	3,4-F	








24. (original) A compound selected from the group consisting of: compounds having the following formula:



wherein R^{4A} , R^1 , R^5 , and R^3 are as defined as follows:


Cpd #	R^{4A}	R^1	-- R^5	-- R^3
-------	----------	-------	----------	----------

AMENDMENT
U.S. Appln. No. 10/772,721


Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³	
A1001	Na	--	3,4-Br	 stereochemistry undetermined	;
A1002	Na	--	3,4-Br	 stereochemistry undetermined	;
A1006	Na	mixture b-Me & c-Me	3,4-Cl	 stereochemistry undetermined	;
A1007	Na	b-Me	3,4-Cl	 stereochemistry undetermined	;
A1008	Na	c-Me	3,4-Cl	 stereochemistry undetermined	;
A1009	Na	mixture b-Me & c-Me	3,4-Br	 stereochemistry undetermined	;
A1010	Na	b-Me	3,4-Br	 stereochemistry undetermined	; and

AMENDMENT



U.S. Appln. No. 10/772,721

Cpd #	R ^{4A}	R ¹	--R ⁵	--R ³
A1011	Na	c-Me	3,4-Br	 stereochemistry undetermined

25. (original) A compound having the following formula:



wherein R¹, Y, and R³ are as defined as follows:

Cpd #	R ¹	--Y	--R ³
3013	c-Me		

26. (original) A pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

27. (original) A method for treating a papillomavirus viral infection in a mammal by administering to the mammal an anti-papilloma virus virally effective amount of a compound

AMENDMENT

U.S. Appln. No. 10/772,721

of formula (I), according to claim 1, or a therapeutically acceptable salt or ester thereof, or a pharmaceutical composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

28. (original) A method for inhibiting the replication of papillomavirus by exposing the virus to an amount of a compound of formula (I), according to claim 1 inhibiting the papilloma virus E1-E2-DNA complex, or a therapeutically acceptable salt or ester thereof, or a composition comprising an anti-papillomavirus virally effective amount of a compound of formula (I) according to claim 1, or a therapeutically acceptable salt or ester thereof, in admixture with a pharmaceutically acceptable carrier medium or auxiliary agent.

29. (original) A method of preventing perinatal transmission of HPV from mother to baby, by administering a compound of formula (I), according to claim 1, to the mother prior to giving birth.